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ABSTRACT 
The objective of the present study is to develop colon targeted drug delivery system using dextrin (polysaccharide) as a carrier for Azathioprine.  
Microspheres containing azathioprine, dextrin and various excipients were prepared by solvent evaporation technique. The prepared 
microsphere were evaluated by different methods parameters like particle size,  drug entrapment efficiency, percentage yield, shape and surface 
morphology  and in vitro drug release study. Drug release profile was evaluated in simulated gastric, intestinal fluid and simulated colonic fluid. 
Best formulation was decided on the basis drug release profile in simulated gastric, intestinal fluid and simulated colonic fluid. In dextrin based 
microspheres, dextrin as a carrier was found to be suitable for targeting of Azathioprine for local action in the site of colon. Dextrin microspheres 
released 95-99% of azathioprine in simulated colonic fluid with 4% human fecal matter solution. The results of in-vitro studies of the 
azathioprine microspheres indicate that for colon targeting dextrin are suitable carriers to deliver the drug specifically in the colonic region. 
Dextrin based azathoprine microspheres showed no significance change in particle size and % residual upon storage at 5 ± 3ºC, 25 ± 2ºC/60 ± 
5% RH (room temperature) and 40 ± 2ºC/75 ±5%RH humidity for three months.  
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1. INTRODUCTION  
Since from last decade a novel oral colon-specific drug 
delivery system (CDDS) has been developing as one of the 
site-specific drug delivery systems. This delivery system, by 
means of combination of one or more controlled release 
mechanisms, this system hardly allow to releases drug in the 
upper part of the gastrointestinal (GI) tract, but rapidly 
releases drug in the site of colon following oral 
administration1, 2, 3. CDDS is convenient for treating localized 
colonic diseases, i.e. ulcerative colitis, Crohn’s disease and 
constipation etc., CDDS, also selectively deliver drug to the 
colon, but not to the upper GI tract 1. Colon is referred to as 
the optimal absorption site for protein and polypeptide after 
oral administration, because of the existence of relatively 
low proteolytic enzyme activities and quite long transit time 
in the colon. CDDS would be advantageous when a delay in 
absorption is desirable from a therapeutically point of view, 
as for the treatment of diseases that have peak symptoms in 
the early morning and that exhibit circadian rhythms, such 
as nocturnal asthma, angina and rheumatoid arthritis 1, 2, 4.  
 There were currently a few strategies to achieve colonic 
specificity, such as use of pH sensitive polymers and 
pressure-controlled CDDS. The aim of this study was to 
explore the feasibility of the colonic microorganism to 
develop CDDS by using azathioprine and budesonide as a 
model drugs 1, 5.  
Polysaccharides, the monosaccharide polymer retains their 
integrity because they are resistant to the digestive action of 
gastrointestinal enzymes of stomach. The matrices of 
polysaccharides are assumed to remain intact in the 
physiological environment of stomach and small intestine 
but once they reach in the colon, they are acted upon by the 
bacterial polysaccharides and results in the degradation of 
the matrices. A large number of polysaccharides such as 
amylose, guar gum, pectin, chitosan, inulin, cyclodextrins, 
chondroitin sulphate, dextrans, dextrin and locust bean gum 
have been investigated for their use in colon targeted drug 
delivery systems. The most important fact in the 
development of polysaccharide derivatives for colon 
targeted drug delivery is the selection of a suitable 
biodegradable polysaccharide. As these polysaccharides are 
usually soluble in water, they must be made water insoluble 
by cross linking or hydrophobic derivatisation, very 
important is an optimal proportional of the hydrophobic and 
hydrophilic parts respectively and the number of free 
hydroxyl groups in the polymeric molecule.  The objective of 
the present study is to develop colon targeted drug delivery 
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system by using dextrin as a carrier for Azathoprine. CDDS is 
also selectively delivered drug to colon but not to the upper 
tract 6, 7.  
2. MATERIAL AND METHODS 
Azathioprine was obtained from Sun Pharmaceuticals 
Limited, Mumbai. Dextrin and Span 80 was purchased from 
Sigma Aldrich Pvt Ltd. All other ingredients, solvents used 
for assay were of analytical grade.  
Method 
The azathioprine microspheres were prepared by solvent 
evaporation method.  The drug (azathioprine) and dextrin 
(1%, 5%, 10% & 20% w/v) were dissolved in 
dichloromethane. This solution was dispersed in 100 ml of 
liquid paraffin light containing various concentration of Span 
80 in a 250 ml beaker. The dispersion was stirred at 200 rpm 
for 30 min. After the stirring time, microspheres were 
centrifuged, washed several times with n-hexane, ether and 
finally with acetone. The microspheres were dried at 50˚C 
and stored in desiccator 8. Than optimization done on the 
basis of drug concentration, stirring time, surfactant 
concentration, temperature, and polymer concentration 
shown in table 1. Total 19 batches were prepared for 
azathioprine microspheres. In which 4 formulations were 
prepared with different drug polymer ratio. These 4 
formulation of azathioprine microspheres further evaluated. 
 
Table 1: Optimization of Azathioprine microspheres 
Formulation 
code 
Drug in 
Mg 
Span 80 
(%w/w) 
Stirring 
speed (rpm) 
Temperature Dextrin 
(%w/v) 
Mean size 
(µm) 
% drug 
entrapment 
efficiency 
F1 A 25 0.5 400 37 º 5 83±2.8 94.2±1.4 
F2 A 50 - - - - 85±1.9 83.5±1.8 
F3 A 75 - - - - 87±1.8 78.8±1.2 
F4 A 100 - - - - 88±1.2 74.3±2.8 
F5 A 25 0.5 400 37 º 5 75.81.2 92.81.4 
F6 A - 0.75 - - - 73.90.9 74.81.2 
F7 A - 1.0 - - - 71.21.2 72.52.6 
F8 A - 1.25 - - - 70.21.6 68.72.2 
F9 A 25 0.5 200 37 º 5 80.22.2 92.61.4 
F10 A - - 300 - - 76.41.8 84.32.6 
F11 A - - 400 - - 72.31.6 81.62.6 
F12 A - - 500 - - 66.21.2 79.62.4 
F13A 25 0.5 200 25 º 5 71.32.2 83.81.6 
F14 A - - - 37 º - 76.21.8 92.61.6 
F 15 A - - - 45 º - 78.21.8 
78.21.6 
F16 A 25 0.5 200 37 º 1 75.41.6 76.81.2 
F17 A - - - - 5 82.81.2 83.51.8 
F18 A - - - - 10 85.40.9 95.21.4 
F 19 A - - - - 20 78.51.2 83.51.8 
 
Evaluation Parameters  
The prepared microspheres of Azathioprine drug were 
evaluated for particle size, drug entrapment efficiency, 
percent yield, invitro release studies and stability studies.  
Particle size analysis  
The particle size of microspheres was determined using 
optical microscopy method. Particle size of all the batches of 
azathioprine microspheres and budesonide microspheres 
sample was measured with an optical micrometre fitted with 
a calibrated eye piece. Approximately 200 particles were 
counted for particle size using a calibrated optical 
microscope. All readings are average of three trials ± SD 9.  
Drug entrapment efficiency 
Drug entrapment efficiency Drug entrapment efficiency of 
Azathioprine microspheres was performed by accurately 
weighing 100 mg of drug equivalent microspheres and 
suspended in 100 ml of 7.4 pH phosphate buffer and it was 
kept on a side for 24 hours. Then, it was stirred for 15 mints 
and filtered. After suitable dilution, azathioprine in the 
filtrate was analyzed spectrophotometrically at 280 nm 
using U.V. Spectrophotometer 10. 
                   
                             
                              
     
Percentage yield 
The prepared azathioprine microspheres with a size range of 
60-90 µm were collected and weighed from different 
formulations. The measured weight was divided by the total 
amount of all non-volatile components which were used for 
the preparation of the microspheres 11. 
         
                       
                               
     
Scanning electron microscopy analysis (SEM) 
 The shape and surface characteristics were determined by 
scanning electron microscopy (model-JSM, 35CF, jeol, Japan).  
Sample was fixed on carbon tape and fine gold sputtering 
was applied in a high vacuum evaporator. The acceleration 
voltage was set at 3.0 KV during scanning. Microphotographs 
were taken on different magnification and higher 
magnification (500X) was used for surface morphology.  
In vitro drug release study 
Test were carried out for azathioprine microspheres using 
separate USP apparatus II (paddle) and the medium was 
Simulated gastric fluid, Simulated intestinal fluid and 
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simulated colonic fluid, individually. Quantity of dissolution 
medium was 900 mL. The speed of paddle was 50 rpm and 
temperature of dissolution medium was 37.5o C. The 
accurately weighed azathioprine microspheres were placed 
in the dissolution medium and apparatus was run. At 
intervals of 2, 5, 8, 12, 16, 20 and 24 hours, 5 mL aliquots 
were withdrawn and replacement was made each time with 
5 mL of fresh dissolution medium 6. Each 5 mL sample was 
filtered through Whatman filter paper no. 41 and diluted up 
to 50 ml with respective dissolution medium. Then 
absorbance was measured at 280 nm 12. 
Stability Study 
 Stability studies were carried out at5 ± 3ºC, 25 ± 2ºC/60 ± 
5% RH (room temperature) and 40 ± 2ºC/75 ±5% RHfor the 
optimized formulation F18 A and F18 B for 3 months. The 
samples were withdrawn after predetermined period of 1 
month, 2 month and 3 month. The samples were analyzed for 
its particle size and % residual drugs 13. 
Drug Release Kinetics 
Zero order release rate kinetics 14  
To study the zero order release kinetics the release rate data 
are fitted to the following equation F=K0t  
Here, F is the fraction of drug release  
K0 is the rate constant  
T is the release time 
First order model  
This model has also been used to describe absorption 
and/elimination of drug, the release of the drug which 
followed first order kinetic can be expressed by the equation  
 Log C=log c0-kt/2.303 
 Where, Co is the initial concentration of drug 
 K is the first order rate constant 
 t = is the time 
Higuchi release model  
To study the higuchi release kinetics, the release rate data 
was fitted to the following equation 
 F =KH.t1/2  
Where, F is the amount of the drug release 
Kh is the release time 
t is the release time  
Korsmeyer and peppas model  
The release rate date were fitted to the following equation, 
 Mt/M8 =KM.tn Where, 
 Mt/M8 is the fraction of drug release 
 KM is the release constant t is the release time. 
3. RESULTS AND DISCUSSION 
Evaluation parameters of microsphere 
Microspheres of azathioprine were prepared successfully by 
solvent evaporation method. The various parameters in the 
production of microspheres were evaluated and reported in 
Table 1. The particle size study was found to be between 
75.4 ±1.6 to 85.4 ± 0.9 of F16 A - F19 A. The particle size of 
microspheres increased with increases in the polymer 
concentration. The drug entrapment efficiency was found to 
be range of 76.8  1.2 to 95.2  2.1. Initially the entrapment 
efficiency microspheres is increased with increasing the 
polymer concentration but after optimum condition 
entrapment efficiency is decreased due to less amount of 
drug available as compare to polymer for entrapment. The 
Percent yield was found to be between 71.56  1.4 to 84.23  
2.5. The shape and surface characteristics were determined 
by scanning electron microscopy and report shows in Fig 1.  
 
Figure 1: SEM image of optimized formulation F 18 A 
Dissolution Studies 
All the F16 A – F19 A formulations of azathioprine 
microspheres are subjected to dissolution studies. 
Dissolution is carried out in USP type II apparatus at 50 rpm 
in the volume of 900ml dissolution medium was simulated 
gastric fluid, simulated intestinal fluid and simulated colonic 
fluid for 24 hours. The results are shown in Table 2 and Fig.2. 
 
Table 2: Release study of Formulation F16 A- F19 A 
Simulated Media 
(pH) 
Time in 
Hours 
F16 A F17 A F18 A F19 A 
Cumulative % Drug release 
SIF 1.2 1 15.42 10.17 4.23 11.40 
2 26.30 18.58 8.96 20.86 
SIF 6.8 5 40.22 36.56 12.64 34.70 
SCF 7.4 8 60.32 68.84 56.20 62.17 
 12 68.46 72.08 68.00 73.32 
16 75.37 89.40 86.80 84.39 
20 83.92 92.82 95.50 90.46 
24 96.70 98.08 99.01 97.20 
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Figure 2: Release study of formulation F16 A - F19 A 
 
Drug release studies shows that F18 A shows good release 
behavior in colon and restricts release in stomach and 
intestine as compare to F16 A, F17 A, and F19 A. Because 
dextrin is degraded by the enzymes presented in the colonic 
region hence this study confirms that for colon targeting by 
dextrin can act as good carrier.  
Stability study of formulation F 18 A confirms that 
microsphere are more stable in refrigerator condition  at  5 ± 
3º and there was no significant change occurs in particle size 
and % residual drug content of F18 A. 
The Fig. 2 indicates F18 formulation shows better drug 
release when compared with other formulations, and 
followed by the first order kinetics. The mechanism of 
release F18 A formulation as shown in Fig 3-6. 
 
Figure 3: Zero order release kinetics of F18 A 
 
Figure 4: First order release kinetics of F18 A 
 
Figure 5: Higuchi order release kinetics of F18 A 
 
Figure 6: Korsemayer – Peppas release kinetics  of F18 A 
4. CONCLUSION 
Drug release studies showed that Dextrin based azathioprine 
microspheres shows good release behaviour in colon and 
restricts release in stomach and intestine. This study 
confirms that for colon specific targeting, dextrin can act as 
good carrier which delivers the more amount of drug 
specifically in colon.  
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